Competition & Markets Authority
CMA accuses pharma firms of illegal pricing
The CMA has provisionally found that Pfizer and Flynn abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case.
Having gathered further evidence and after carefully assessing the facts, the Competition and Markets Authority (CMA) has reached a provisional view – known as a Statement of Objections – that Pfizer and Flynn broke competition law by charging unfairly high prices for phenytoin sodium capsules.
The CMA has provisionally found that the companies exploited a loophole by de-branding the drug – known as Epanutin prior to September 2012 – with the effect that the drug was not subject to price regulation in the way branded drugs are. As Pfizer and Flynn were the dominant suppliers of the drug in the UK, the NHS had no choice but to pay unfairly high prices for this vital medicine.
Following the overnight price increases by the companies, NHS spending on phenytoin sodium capsules rose from around £2 million a year in 2012 to about £50 million in 2013. For over 4 years, Pfizer’s prices were between 780% and 1,600% higher than it had previously charged. Pfizer then supplied the drug to Flynn, which sold it to wholesalers and pharmacies at prices between 2,300% and 2,600% higher than those they had paid previously.
In December 2016, following an in-depth investigation, the CMA fined Pfizer and Flynn for breaking competition law by charging unfairly high prices for phenytoin sodium capsules.
The companies appealed against the CMA’s decision that competition law had been broken and against the fine. In June 2018, the Competition Appeal Tribunal (CAT) upheld the CMA’s findings on market definition and dominance but set aside the CMA’s finding that the companies’ prices were an unlawful “abuse” of dominance. The CAT referred the matter of abuse back to the CMA for further consideration – known as a remittal.
The CMA and Flynn then appealed to the Court of Appeal. In March 2020 the Court dismissed Flynn’s appeal in its entirety and upheld aspects of the appeal brought by the CMA relating to the application of the legal test for unfair pricing. Following this, the CMA decided to re-investigate the matters remitted by the CAT and opened its current investigation in June 2020.
Andrea Coscelli, Chief Executive of the CMA, yesterday said:
Thousands of patients depend on this drug to prevent life-threatening seizures as a result of their epilepsy. As the CAT recognised, this is a matter that is important for government, for the public as patients and taxpayers, and for the pharmaceutical industry itself. Protecting these patients, the NHS and the taxpayers who fund it, is our priority.
The CMA’s findings are, at this stage, provisional. Pfizer and Flynn now have an opportunity to respond to the provisional findings set out in the Statement of Objections and the CMA will carefully consider their representations before deciding whether they broke the law.
The CMA remains committed to its work to tackle robustly any illegal behaviour by drug companies overcharging the NHS. It recently fined firms £260 million for competition law breaches in relation to the supply of hydrocortisone tablets and £100 million for competition law breaches in relation to the supply of liothyronine tablets. A number of other CMA investigations are continuing.
For more information see the phenytoin sodium capsules: suspected unfair pricing case page.
Media queries should be directed to email@example.com or call 020 3738 6460.
Latest News from
Competition & Markets Authority
Sale of emergency service software businesses required to protect UK taxpayers01/12/2022 15:25:00
NEC must sell some parts of its business after an in-depth merger investigation found that publicly-funded emergency services could end up paying more for essential software.
CMA investigates online selling practices based on ‘urgency’ claims30/11/2022 11:25:00
The CMA is investigating Emma Sleep over concerns that some of its online sales practices may breach consumer law.
Music streaming report published30/11/2022 10:20:00
The CMA has concluded its independent study into the music streaming market.
Vehicle salvage merger reduces choice and may limit access to salvage vehicles for green parts29/11/2022 12:20:00
Copart’s completed purchase of Hills Motors will reduce the number of salvage services providers available to customers and could limit the vehicles available to suppliers of recycled vehicle parts, often known as ‘green parts’.
Well intervention services deal could result in increased costs for UK oil and gas production23/11/2022 10:15:00
Baker Hughes’ acquisition of Altus could result in oil and gas operators in the UK facing a worse deal for certain well intervention services.
Investigation into cloud gaming and browsers to support UK tech and consumers22/11/2022 14:20:00
The CMA has launched a market investigation into cloud gaming and mobile browsers after receiving widespread support for its proposals first published in June.
Consultation on allowing schools early exit from software contracts17/11/2022 13:20:00
The CMA is consulting on proposals from ESS to allow certain schools to exit longer-term software contracts where the CMA has concerns that the lack of notice given to them limited their choice and competition.
CMA accepts remedy to address concerns in foam merger17/11/2022 09:20:00
The CMA has accepted a remedy from Carpenter and Recticel following concerns that Carpenter’s merger with Recticel could harm manufacturers and lead to a worse deal for shoppers on items like mattresses and kitchen sponges.